Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Leukemia 11Leukemia, Myeloid, Acute 9Lymphoma, Non-Hodgkin 7Lymphoma 7Myelodysplastic Syndromes 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Burkitt Lymphoma 4Blast Crisis 4Waldenstrom Macroglobulinemia 3Neoplasms 3Multiple Myeloma 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Graft vs Host Disease 3Congenital Abnormalities 3Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myelomonocytic, Chronic 2

Interventions

Cisplatin 7Etoposide 6Amifostine 6Radiotherapy 5Drug Therapy 5Cyclophosphamide 5apatinib 4Methotrexate 4Filgrastim 4Cytarabine 4sodium thiosulfate 3Methylprednisolone 3Carboplatin 3pegfilgrastim 2glucarpidase 2etoposide phosphate 2Voriconazole 2Vincristine 2Social Determinants of Health 2Pyridoxine 2Nivolumab 2Gemcitabine 2Doxorubicin 2Docetaxel 2Chemotherapy, Adjuvant 2Capecitabine 2trastuzumab deruxtecan 1selinexor 1sargramostim 1sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Drug-Related Side Effects and Adverse Reactions × Methylprednisolone Hemisuccinate × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡